Arcalyst is a first-in-class drug designed using Regeneron's 'Trap' technology. The drug is a fusion protein comprising the human interleukin (IL)-1 type 1 receptor (extracellular domain and ...
Xenetic (XBIO) Biosciences announced the presentation of positive preclinical data. The poster titled, ” DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade ...